Skip to content
TrialMatch
Sign up
Recruiting Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

Condition
Alzheimer's Disease
Tested
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo
Sponsor
Bristol-Myers Squibb

Who can join

Age
55 to 90 years
Sex
All sexes
Healthy volunteers
Not accepted

Inclusion 18

  • Minimum age: 55 years
  • Maximum age: 90 years
  • Study condition: Alzheimer's Disease
  • \- A diagnosis of Alzheimer's disease (AD) in accordance with the 2024 Alzheimer's Association criteria with one of the following confirmations of AD pathology:
  • i) Historical evidence of AD diagnosis with amyloid positron emission tomography (PET), Aβ42/40 ratio in CSF, pTau181/Aβ42 ratio in CSF or pTau217/Aβ42 ratio in plasma using an Health Authority (HA)-authorized diagnostic assay.
  • ii) If no historical evidence available:
  • A. A plasma biomarker will be assessed for eligibility if allowed per regulatory requirements. The test cutoff(s) will be based on diagnostic use approval.
  • B. If a plasma biomarker assay cannot be used or if the assay result is inconclusive, conduct one the following:
  • Amyloid PET.
  • Aβ42/40 ratio or pTau181/Aβ42 ratio in CSF using an HA-authorized diagnostic assay.
  • Mini-Mental State Examination (MMSE) score of ≤ 24 at Screening (Visit 1).
  • Have an identified caregiver who has sufficient contact (approximately 8 hours over a week) and is willing to:
  • i) Attend all visits and report on participant's status.
  • ii) Oversee participant compliance with medication and study procedures.
  • iii) Participate in the study assessments and provide informed consent to participate in the study.
  • History of agitation that meets the International Psychogeriatric Association (IPA) consensus definition for agitation in cognitive disorders with onset at least two weeks prior to Screening (Visit 1).
  • AD participants are required to have NPI/NPI-NH Agitation/Aggression score ≥ 4 at Screening (Visit 1) and Baseline (Visit 2).
  • Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association (CMAI-IPA) Total Score ≥ 30 at Screening (Visit 1) and Visit 2.

Exclusion 11

  • \- Medical Conditions.
  • i) Agitation symptoms that are primarily attributable to a condition other than the AD causing the dementia.
  • ii) History of bipolar disorder, schizophrenia, or schizoaffective disorder.
  • iii) History of (or at high risk for) urinary retention, gastric retention, or narrow-angle glaucoma as evaluated by the Investigator.
  • iv) Risk of suicidal behavior during the study as determined by the Investigator's clinical assessment and/or C-SSR.
  • \- Prior/Concomitant Therapy.
  • i) Recent history of receiving monoamine oxidase inhibitors, anticonvulsants (eg, lamotrigine, divalproex), mood stabilizers (eg, lithium), tricyclic antidepressants (eg, imipramine, desipramine), or any other psychoactive medications except for as needed anxiolytics (eg, lorazepam).
  • A. Selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors taken at a stable dose for at least 8 weeks prior to Screening (Visit 1) may be permitted.
  • B. Trazodone may be used as a hypnotic or for agitation if started at least 8 weeks prior to Screening (Visit 1).
  • Note: Mirtazapine may be used as a hypnotic if started at least 8 weeks prior to Screening (Visit 1).
  • \- Other protocol-defined Inclusion/Exclusion criteria apply.

Where

144 sites, 129 recruiting

Fundacion para el Estudio y Tratamiento de Enfermedades mentales- FETEM

Buenos Aires, Argentina

Recruiting

Hospital Italiano de Buenos Aires (HIBA)

Buenos Aires, Argentina

Recruiting

Centro Neurobiológico y de Estrés Traumático - CENydET S.R.L.

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

Recruiting

Instituto Modelo de Neurología, Fundación Lennox

Córdoba, Argentina

Recruiting

Sanatorio Morra S.A.

Córdoba, Argentina

Recruiting

Instituto Médico DAMIC

Córdoba, Argentina

Recruiting

and 138 more sites on ClinicalTrials.gov

Contact

  • BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

    855-907-3286 Clinical.Trials@bms.com

  • First line of the email MUST contain NCT # and Site #.

Potential match only. Final eligibility is determined by the study team.